Company Overview of Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The company’s lead drug candidates comprise rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma, as well as in Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate in a randomized Phase IIb study for the treatment of triple negative breast cancer, as well as in Phase II study for the treatment of metastatic melanoma. It also has various earlier stage drug candidates in clinical de...
Perryville III Building
53 Frontage Road
Hampton, NJ 08827
Key Executives for Celldex Therapeutics, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $814.1K
Executive Vice President, Founder and Chief Scientific Officer
Total Annual Compensation: $543.0K
Chief Financial Officer, Principal Accounting Officer, Senior Vice President, Treasurer and Secretary
Total Annual Compensation: $419.1K
Chief Medical Officer and Executive Vice President
Total Annual Compensation: $556.4K
Chief Business Officer and Senior Vice President
Total Annual Compensation: $419.6K
Compensation as of Fiscal Year 2014.
Celldex Therapeutics, Inc. Key Developments
Celldex Therapeutics, Inc. Promotes Richard Wright to Senior Vice President and Chief Commercial Officer
Jul 1 15
Celldex Therapeutics, Inc. announced the promotion of Richard Wright, Ph.D. to Senior Vice President and the newly created position of Chief Commercial Officer. Dr. Wright was previously Vice President of Commercial Operations at Celldex and brings nearly 25 years of industry experience, including the commercialization of six successful drug therapies. As Chief Commercial Officer, Dr. Wright is responsible for developing global business strategy and building the infrastructure required to support commercialization of Celldex's cancer immunotherapy pipeline.
Celldex Therapeutics, Inc. Announces Independent Data Safety and Monitoring Board Recommends Continuation of Phase 3 Study of RINTEGA(R) (Rindopepimut) in Newly Diagnosed Glioblastoma
Jun 29 15
Celldex Therapeutics, Inc. announced that an independent Data Safety and Monitoring Board (DSMB) recommended continuation of the Phase 3 ACT IV study of RINTEGA® (rindopepimut) in patients with newly diagnosed glioblastoma. The ACT IV study is a randomized, double-blind, placebo controlled study of rindopepimut plus GM-CSF added to standard of care temozolomide in patients with newly diagnosed, surgically resected, EGFRvIII-positive glioblastoma. 745 patients were enrolled into ACT IV to reach the required 374 patients with minimal residual disease (assessed by central review) needed for analysis of the primary overall survival endpoint. All patients, including those with disease that exceed this threshold, will be included in a secondary analysis of overall survival as well as analyses of progression-free survival, safety and tolerability, and quality of life. The timing of the overall survival primary endpoint data is event-driven. Interim analyses assessing safety, futility and efficacy conducted by an independent DSMB were prespecified at 50% and 75% of events.
Celldex Therapeutics, Inc. - Special Call
May 31 15
To discuss the ReACT data
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|